This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Drug Therapy  • Adverse Effects  • Allergy  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Kerstin Hellwig, MD; Sebastian Schimrigk, MD; Malte Fischer, MD; Aiden Haghikia, MD; Thomas Müller, MD; Andrew Chan, MD; Ralf Gold, MD

Arch Neurol. 2008;65(5):656-658.

Background  The monoclonal antibody natalizumab is a novel therapeutic option in the treatment of relapsing forms of multiple sclerosis. In general, therapy with natalizumab is well tolerated. Allergic reactions and acute infusion reactions typically occur during or shortly after infusion, with a peak at the second infusion. Delayed infusion reactions resembling serum sickness–type reactions (type III reaction) are commonly reported in other monoclonal antibody therapies (eg, infliximab and rituximab), but are not described yet for natalizumab.

Results  Delayed infusion reactions occurred in 4 of 40 relapse-remitting multiple sclerosis patients treated with natalizumab.

Conclusions  Clinicians need to consider the occurrence of infusion reactions, with especially delayed reactions occurring more frequently than previously assumed. Our cases illustrate that some of these infusion reactions may be treated effectively with steroids and reduction of the infusion rate. In cases of antibody-mediated reactions, treatment should be stopped immediately.

Author Affiliations: Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy
Coyle et al.
Mult Scler 2009;15:S26-S36.
ABSTRACT  

RECURRENT PERICARDITIS DUE TO NATALIZUMAB TREATMENT
Cohen et al.
Neurology 2009;72:1616-1617.
FULL TEXT  

Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies
Killestein et al.
Mult Scler 2009;15:525-526.
 

Review: Natalizumab in the treatment of multiple sclerosis
Yaldizli and Putzki
Therapeutic Advances in Neurological Disorders 2009;2:115-128.
ABSTRACT